Translate

CORONAVIRUS COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) ...

domingo, 1 de julio de 2018

Posibilidades de progresar a demencia de personas con señales preclínicas de enfermedad de Alzheimer

Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease

Highlights

  • •Lifetime risks of AD dementia vary by age, gender and preclinical disease state.
  • •Most persons with preclinical AD will not develop AD dementia during their lifetimes.
  • •Lifetime risks assist in interpreting biomarker screening tests for preclinical AD.

Abstract

Introduction


Lifetime risks are the probabilities of progressing to Alzheimer's disease (AD) dementia during one's lifespan. Here, we report the first estimates of the lifetime and ten-year risks of AD dementia based on age, gender, and biomarker tests for preclinical disease.

Methods


We used a multistate model for the disease process together with US death rates.

Results


Lifetime risks of AD dementia vary considerably by age, gender, and the preclinical or clinical disease state of the individual. For example, the lifetime risks for a female with only amyloidosis are 8.4% for a 90-year old and 29.3% for a 65-year old. Persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration have lifetime risks of AD dementia greater than 50%.

Discussion


Most persons with preclinical AD will not develop AD dementia during their lifetimes. Lifetime risks help interpret the clinical significance of biomarker screening tests for AD.

No hay comentarios:

Publicar un comentario

Aportes